C4 Therapeutics (CCCC) Cash & Equivalents Growth (1y) (2020 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 28.50% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -57.58% |
| 10 | C4 Therapeutics | 499.92 Mn | 246.25 Mn | - | 0.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.58% |
| Mar 31, 2026 | 19.46% |
| Dec 31, 2025 | 34.42% |
| Sep 30, 2025 | -1.41% |
| Jun 30, 2025 | 6.90% |
| Mar 31, 2025 | -42.79% |
| Dec 31, 2024 | -56.16% |
| Sep 30, 2024 | -2.17% |
| Jun 30, 2024 | 62.91% |
| Mar 31, 2024 | 81.22% |
| Dec 31, 2023 | 325.46% |
| Sep 30, 2023 | 23.05% |
| Jun 30, 2023 | -21.67% |
| Mar 31, 2023 | 7.55% |
| Dec 31, 2022 | -60.91% |
| Sep 30, 2022 | -69.55% |
| Jun 30, 2022 | -79.62% |
| Mar 31, 2022 | -51.53% |
| Dec 31, 2021 | -79.43% |
| Sep 30, 2021 | 156.56% |